Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax + atezolizumab + obinutuzumab in Richter transformation of CLL
2018-005028-40Phase 2Active
- Sponsor
- ASST Grande Ospedale Metropolitano Niguarda
- Start
- Jan 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax, atezolizumab and obinutuzumab in Richter's syndrome (RS) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by ASST Grande Ospedale Metropolitano Niguarda. Primary endpoint: Overall response rate at end of cycle 6. Started Jan 2021; status: active.
02
Drugs
venetoclaxatezolizumabobinutuzumab
03
Conditions
Richter's syndrome (RS)chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2018-005028-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-005028-40.